Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke

Nunaps

Status: Completed

Conditions: Hemianopsia, Homonymous; Visual Fields Hemianopsia

Treatments: Other: No-treatment Control; Device: VIVID Brain

Study type: Interventional

Funder types: Industry

Identifiers

NCT05525949

NNS-VB-02

Details and patient eligibility

About

This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain disease. Half of participants will receive visual perceptual training using the VIVID Brain. The other half will not receive any training because there is no standard treatment for visual field defect caused by brain disease.

Enrollment: 93 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 19 years and older
• At least 3 months after brain disease related to visual field defect
• Verified brain disease in visual pathway related to occipital lobe, parietal lobe, temporal lobe or etc. using CT or MRI
• Brain disease induced visual field defect
• Able to use the VR(Virtual Reality) device
• Able to use the app with a smart phone
• Patient/legally authorized representative has signed the informed consent form

Exclusion criteria

• Complete hemianopsia
• Epilepsy, photosensitivity, Parkinson's disease
• Bilateral visual field defect
• Hemispatial neglect
• Ophthalmologic disorder that may interfere the trial. (Ptosis of Eyelid, Corneal Opacity, Diabetic Retinopathy, Glaucoma, Macular Degeneration etc.)
• Inability to discontinue psychostimulants such as methylphenidate, modafinil, and amphetamine.
• Candidate for carotid endarterectomy or stenting
• Received ophthalmologic surgery or laser surgery within 3 months, except for the cataract surgery
• Pregnant or breast feeding
• Participating in other clinical trial
• Any other condition that, in the opinion of the investigator, precludes participation in the trial

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

93 participants in 2 patient groups

VIVID Brain

Experimental group

Description:

VIVID Brain, 5 times a week for 12 weeks

Treatment:

Device: VIVID Brain

No-treatment Control

Other group

Description:

No-treatment is administered during control period.

Treatment:

Other: No-treatment Control